The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

and advanced cervical cancer. In the?US, the generic name for Libtayo in its approved?indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Helping Libtayo reach its potential was a 2022 nod to treat newly diagnosed non-small cell lung cancer (NSCLC), allowing it to compete with Merck’s powerhouse PD-1 drug Keytruda. More growth ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens. Treatment with the lead clinical candidate THIO ...

CSCC is the second most common type of skin cancer, with approximately 1.8 million cases diagnosed in the US every year. Libtayo is designed to block cancer cells from using the PD-1 pathway to ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.